Abstract
Objective: to identify the most cost-effective treatment for depression in Colombia. Population: women and men older than 19 years
old, with a recent depression diagnosis, which were attended in primary attention and had not received any previous treatment.
Compared alternatives: most frequently used and available drugs in Colombia for depression management.
Perspective: from the health system
Outcome: impact on initial response, remission of signs of depression, relapse and abandonnement.
Economic outcome: incremental cost for quality-adjusted life year
Time horizon: 15 months
Information source: transition probabilities were extracted from the literature. Costs were estimated from depression patient’s health
care bills.
Analysis: estimation of the ratio of incremental cost-effectiveness between dominant alternatives.
Results: Amitriptilina and Fluoxetina are highly cost-effective strategies in the first line treatment for moderated and severe depression, compared to other drugs. Sertralina, at 2012 prices, was the second choice.
old, with a recent depression diagnosis, which were attended in primary attention and had not received any previous treatment.
Compared alternatives: most frequently used and available drugs in Colombia for depression management.
Perspective: from the health system
Outcome: impact on initial response, remission of signs of depression, relapse and abandonnement.
Economic outcome: incremental cost for quality-adjusted life year
Time horizon: 15 months
Information source: transition probabilities were extracted from the literature. Costs were estimated from depression patient’s health
care bills.
Analysis: estimation of the ratio of incremental cost-effectiveness between dominant alternatives.
Results: Amitriptilina and Fluoxetina are highly cost-effective strategies in the first line treatment for moderated and severe depression, compared to other drugs. Sertralina, at 2012 prices, was the second choice.
| Original language | Spanish |
|---|---|
| Pages (from-to) | 185-212 |
| Number of pages | 28 |
| Journal | Coyuntura Económica |
| Volume | 43 |
| Issue number | 2 |
| State | Published - Dec 2013 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Depression
- Drug Therapy
- Cost-Benefit Analysis
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver